Abstract
Background: The early diagnosis of recurrent melanoma can contribute to better outcome if the disease can be surgically resected or if the metastases are responsive to systemic therapies. Lipid-associated sialic acid (LASA-P) and the S-100 protein (S-100) were evaluated as tumor markers for melanoma with the goal of early detection of recurrence.
Methods: Sixty-seven patients were identified who had levels of S-100 and LASA-P drawn during their clinical course. A multivariate regression analysis was performed to determine the significance of the serum markers in relation to other prognostic factors for melanoma.
Results: After a median follow-up of 30 months, 58 patients had recurrences, and 49 patients died of disease. LASA-P elevation was not associated with the time to recurrence (p=0.2176) or survival (p=0.2507). S-100 positivity was a significant predictor of recurrence (p<0.0001) and survival (p=0.0059). The median time to recurrence for S-100-positive and S-100-negative patients was 7.6 and 33.8 months, respectively. The median survival time was 59.2 months for S-100-negative patients and 29.6 months for patients positive for S-100.
Conclusions: Serum S-100 shows significant correlations to both time to recurrence and survival and could be useful in the clinical detection of malignant melanoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schutter EMJ, Visser JJ, van Kamp GJ, et al. The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy: a review of the literature.Tumor Biol 1992;13:121–32.
Katopodis N, Hirshaut Y, Geller NL, Stock CC. Lipid-associated sialic acid test for the detection of human cancer.Cancer Res 1982;42:5270–5.
Reintgen DS, Cruse CW, Wells KE, Saba HI, Fabri PJ. The evaluation of putative tumor markers for malignant melanoma.Ann Plast Surg 1992;28:55–9.
Moore BW. A soluble protein characteristic of the nervous system.Biochem Biophys Res Commun 1965;19:739–44.
Nakajima T, Watanabe S, Sato Y, Kameya T, Shimosato Y, Ishihara K. Immunohistochemical demonstration of S-100 protein in malignant melanoma and pigmented nevus, and its diagnostic application.Cancer 1982;50:912–18.
Stefansson K, Wollmann RL, Moore BW. Distribution of S-100 protein outside the central nervous system.Brain Res 1982;234:309–17.
Fagnart OC, Sindic CJM, Laterre C. Particle counting immunoassay of S-100 protein in serum: possible relevance in tumors and ischemic disorders of the central nervous system.Clin Chem 1988;34(7):1387–91.
Springall DR, Gu J, Cocchia D, et al. The value of S-100 immunostaining as a diagnostic tool in human malignant melanomas: a comparative study using S-100 and neuron-specific enolase antibodies.Virchows Arch Pathol Anat 1983;400:331–43.
Gaynor R, Herschman HR, Irie R, Jones P, Morton D, Cochran A. S-100 protein: a marker for human malignant melanomas?Lancet 1981;1:869–71.
Cho KH, Hashimoto K, Taniguchi Y, Pietruk T, Zarbo RJ, An T. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits.Cancer 1990;66:765–71.
Kaplan FL, Meier P. Nonparametric estimation from incomplete observations.J Am Stat Assoc 1958;52:457–81.
Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration.Cancer Chemother Rep 1966;50:163–70.
Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized trials requiring prolonged observation of each patient II. analysis and examples.Br J Cancer 1997;35:1–39.
Cox DR. Regression models life tables.J R Stat Soc 1972;34:187–220.
Bartolucci AA, Fraser MD. Comparative step-upward composite tests for selecting prognostic indicators associated with survival.Biomet J 1977:19;437–48.
Dorr VJ, Williamson SK, Stephans RL. An evaluation of prostate-specific antigen as a screening test for prostate cancer.Arch Intern Med 1993;153:2529–37.
Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening for prostate cancer.N Engl J Med 1991;324:1156–61.
Woolfson K. Tumor markers in cancer of the colon and rectum.Dis Colon Rectum 1991;34:506–11.
Martin EW, Cooperman M, Carey LC, Minton JP. Sixty second-look procedures primarily by rise in serial carcinoembryonic antigen.J Surg Res 1980;28:389–94.
Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival.Ann Plast Surg 1992;28:45–9.
Clark HB, Santa Cruz D, Hartman BK, Moore BW. S-100 protein, an immunohistochemical marker for malignant melanoma and other melanocytic lesions [Abstract].Lab Invest 1982;46:13A.
Cochran AJ, Wen D-R, Herschman HR, Gaynor RB. Detection of S-100 protein as an aid to the identification of melanocytic tumors.Int J Cancer 1982;30:295–7.
Nakajima T, Watanabe S, Sato Y, Kameya T, Shimosato Y. Immunohistochemical demonstration of S-100 protein in human malignant melanoma and pigmented nevi.Gann 1981;72:335–6.
Stefansson K, Wollmann R, Jerkovic M. S-100 protein in soft-tissue tumors derived from Schwann cells and melanocytes.Am J Pathol 1982;106:261–8.
Kahn HJ, Baumal R, Marks A. The value of immunohistochemical studies using antibody to S-100 protein in dermatopathology.Int J Dermatol 1984;23:38–44.
Kirkwood JM. Present and future applications of the interferons in melanoma [Abstract]. 38th Annual Clinical Conference, Advances in the Biology and Clinical Management of Melanoma. M.D. Anderson Cancer Center, Houston, February 1995.
Cascinelli N. Evaluation of efficacy of adjuvant rIFN-α 2A in melanoma patients with regional node metastases [Abstract 1296].Proc Am Soc Clin Oncol 1995;14:410.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miliotes, G., Lyman, G.H., Wayne Cruse, C. et al. Evaluation of new putative tumor markers for melanoma. Annals of Surgical Oncology 3, 558–563 (1996). https://doi.org/10.1007/BF02306089
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02306089